Anastomotic Outcomes in Idiopathic Pulmonary Fibrosis Patients Receiving Anti-Fibrotic Therapy: Experience of the Australian Lung Transplant Collaborative

被引：0
作者：
Mackintosh, J. [1 ]
Munsif, M. [2 ]
Thomson, C. [3 ]
Musk, M. [4 ]
Snell, G. [2 ]
Glanville, A. [3 ]
Chambers, D. [1 ]
Hopkins, P. [1 ]
机构：
[1] Prince Charles Hosp, Lung Transplant Unit, Brisbane, Qld, Australia
[2] The Alfred, Lung Transplant Serv, Melbourne, Vic, Australia
[3] St Vincents Hosp, Lung Transplant Unit, Sydney, NSW, Australia
[4] Royal Perth Hosp, Lung Transplant Unit, Perth, WA, Australia
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2018年 / 37卷 / 04期
关键词：
D O I：
10.1016/j.healun.2018.01.208
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
205
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [41] LSC Abstract - A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Roach, Katy
    Newby, Chris
    Amrani, Y.
    Bradding, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [42] Evaluation of Extracellular Matrix Biomarkers in Response to Anti-Fibrotic Treatment of Idiopathic Pulmonary Fibrosis
    Jessen, H.
    Hoyer, N.
    Ronnow, S.
    Karsdal, M.
    Leeming, D. J.
    Sand, J. M.
    Shaker, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [43] Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
    Moor, Catharina
    Kimman, Merel L.
    van Manen, Mirjam J. G.
    Dirksen, Carmen D.
    Wijsenbeek, Marlies S.
    Van Jaarsveld, F. Xana
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [44] PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ON ANTI-FIBROTIC TREATMENT WITH PIRFENIDONE OR NINTEDANIB: CLINICAL EVALUATION AND PROGNOSTIC IMPACT
    Stornelli, Silvia Romana
    Lacedonia, Donato
    Scioscia, Giulia
    Simone, Filomena
    Lepore, Giorgia
    Sabato, Roberto
    Giganti, Giulio
    Ciliberti, Gianluca
    Barbaro, Maria Pia Foschino
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [45] Anti-Fibrotic Effects Of Inhaled Interferon-Gamma Detected By Gene Expression In Patients With Idiopathic Pulmonary Fibrosis
    Condos, R.
    Hasaneen, N. A.
    Foda, H. D.
    Smaldone, G. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [46] Efficacy of Anti-Fibrotic Treatments and Prognosis in Progressive Fibrosing Interstitial Lung Diseases Other Than Idiopathic Pulmonary Fibrosis
    Sugino, K.
    Ono, H.
    Shimizu, S.
    Kurosawa, T.
    Ando, M.
    Mori, K.
    Kishi, K.
    Homma, S. A.
    Tsuboi, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [47] Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Karakiulakis, George
    Tamm, Michael
    Lardinois, Didier
    Roth, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [48] Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
    Collins, Bridget F.
    Raghu, Ganesh
    EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
  • [49] Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis
    Sugino, Keishi
    Shimizu, Hiroshige
    Nakamura, Yasuhiko
    Isshiki, Takuma
    Matsumoto, Keiko
    Homma, Sakae
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 899 - 908
  • [50] Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function
    Ebina, M.
    Kimura, Y.
    Ohta, H.
    Hisata, S.
    Tamada, T.
    Nukiwa, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
12345